New onset severe ulcerative colitis following Ixekizumab therapy

Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Morosanu, Alina Mihaela, Mihai, Ioana Ruxandra, Rezus, Ioana Irina, Gavrilescu, Otilia, Dranga, Mihaela, Prelipcean, Cristina Cijevschi, Mihai, Catalina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/
https://www.ncbi.nlm.nih.gov/pubmed/36628163
http://dx.doi.org/10.22551/2022.37.0904.10227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/
https://www.ncbi.nlm.nih.gov/pubmed/36628163
http://dx.doi.org/10.22551/2022.37.0904.10227

Ejemplares similares